San Diego, CA -- (SBWIRE) -- 06/08/2016 -- Immunomedics, Inc is under investigation concerning potential securities laws violations. The investigation was announced for investors in NASDAQ:IMMU shares in connection certain financial statements made by Immunomedics, Inc..

Investors who purchased shares of Immunomedics, Inc. (NASDAQ:IMMU), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements by Immunomedics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 2, 2016, after the market closed, media outlets reported that the American Society of Clinical Oncology ("ASCO") had removed a scheduled presentation by Immunomedics regarding the Company's IMMU-132 breast cancer drug from the American Society of Clinical Oncology's annual meeting. The American Society of Clinical Oncology stated that Immunomedics, Inc. had misrepresented that the Company's abstract for IMMU-132 contained updated and previously undisclosed results from a mid-stage study, when in fact the IMMU-132 data that Immunomedics submitted were old and previously seen.

Shares of Immunomedics, Inc. (NASDAQ:IMMU) declined to as low as $3.83 per share on June 6, 2016.

Those who purchased shares of Immunomedics, Inc. (NASDAQ:IMMU) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com